Gastroesophageal reflux disease. Gastro-esophageal reflux disease
Conditions
Interventions
Intervention 1: Intervention group 1: In this group, patients will receive two Mastic capsules (each containing 500 mg of Mastic) three times a day for 4 weeks (Prepared from Toba Pharmacy -Ostad Naze
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Men and women 18 years old and older Heartburn at least once a week Reflux from the stomach into the esophagus and mouth Basic literacy (at least reading and writing skills)
Exclusion criteria
Exclusion criteria: Taking anti-re flux medications warning signs including weight loss, anemia, severe vomiting and food sting in those who have not been evaluated by endoscope Barrett's esophagus Esophagitis with non-reflux causes Taking NSAID Drugs Pregnancy Systemic diseases (liver disease, kidney disease, uncontrolled diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of days the patient has heartburn (A burning feeling behind breastbone). Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: Frequency scale for the symptoms of gastroesophageal reflux disease questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of days the patient has regurgitation (stomach contents (liquid or food) moving upwards to throat or mouth). Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: FSSG (Frequency scale for the symptoms of gastroesophageal reflux disease).;The number of days the patient has pain in the stomach (heartburn). Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: FSSG (Frequency scale for the symptoms of gastroesophageal reflux disease).;The number of days the patient has nausea. Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: FSSG (Frequency scale for the symptoms of gastroesophageal reflux disease).;The number of days the patient hasn't slept well due to heartburn or regurgitation. Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: FSSG (Frequency scale for the symptoms of gastroesophageal reflux disease).;The number of days the patient uses other drugs in addition to previously prescribed medications due to heartburn or reflux. Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: FSSG (Frequency scale for the symptoms of gastroesophageal reflux disease).;Quality of life. Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measurement: GERD_Quality of life questionnaire.;Duration of drug intaking. Timepoint: At the beginning of the study. Method of measurement: Interview.;Drug side effects. Timepoint: At the beginning of the study, 4 weeks during the intervention and 2 weeks after the end of the intervention. Method of measuremen | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba Sadeghi
Tabriz University of Medical Sciences
Outcome results
None listed